Ohio State Launches Groundbreaking First-in-Human Cancer Drug Trial
Asrar Alahmadi, Thoracic Medical Oncologist in Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn by Carol Bradford, Dean of The Ohio State University College of Medicine, adding:
“I’m truly grateful for Dean Carol Bradford kind words and support. This trial represents the vision, persistence, and teamwork of so many brilliant scientists and clinicians at The OSUCCC – James.
It is a privilege to help bring forward a first-in-human therapy developed entirely at Ohio State, with the hope of expanding options for patients facing advanced cancers.
Proud to be part of this journey and excited to see what’s ahead.”
Quoting Carol Bradford‘s post:
“I am blown away by the incredible research team at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute for developing a promising new cancer drug. This first-in-human clinical trial targets a tumor growth enzyme that helps cancer cells thrive. The drug, developed entirely at Ohio State, is now being tested in patients with advanced solid tumors and non-Hodgkin lymphoma who have limited treatment options.
Special thanks to Dr. Asrar Alahmadi, an assistant professor in the Division of Medical Oncology and the clinical trial’s principal investigator, for leading this groundbreaking study. ”
Title: Cancer drug developed at Ohio State now in clinical trial for people with limited treatment options
Author: Bob Hecker
Read the Full Article at the Ohio Stet University’s website.
More posts featuring Asrar Alahmadi on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023